Eli Lilly Cuts Q4 Revenue Guidance, Expects Around $5.5 Billion …
1 day ago · Eli Lilly expects fourth-quarter 2024 revenue of approximately $13.5 billion, representing a 45% year-over-year growth compared to the consensus of $13.97 billion. ... Eli Lilly Cuts Q4 Revenue ...
Lilly provides update on 2024 revenue guidance, announces 2025 …
1 day ago · For Q4 2024, Lilly now expects worldwide revenue to be approximately $13.5 billion, representing growth of 45% compared to Q4 2023. This includes approximately $3.5 billion for Mounjaro ® and $1.9 billion for Zepbound ®. In addition to the uptake of Mounjaro and Zepbound, Lilly saw strong performance from its oncology, immunology and ...
Quarterly Results | Eli Lilly and Company
The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
Eli Lilly Cuts Q4 Forecast Amid Weak Sales but Sees Bright 2025 …
1 day ago · Eli Lilly revises Q4 revenue down on slower U.S. incretin market growth, eyes robust 2025 projections. ... Eli Lilly voiced hope for its long-term performance. The company expects income for ...
Eli Lilly Cuts Q4 Sales Forecast: ETFs to Buy on the Dip - Yahoo …
7 hours ago · Eli Lilly also cut its revenue guidance for full-year 2024 to $45 billion from the previous expectation of $45.4-$46 billion. The new outlook still indicates 32% year-over-year growth in revenues.
Lilly Cuts Q4 Revenue View Below Market, Lifts FY24 Outlook; …
1 day ago · Lilly now expects approximately $3.5 billion for Mounjaro and $1.9 billion for Zepbound. In total, non-incretin revenue grew by 20 percent. However, the company's expected 2024 revenue is about 3 ...
Eli Lilly Cuts 4Q Sales Outlook After Slower-Than ... - Morningstar
1 day ago · "Sales of Mounjaro and Zepbound posted robust sales growth in Q4, and we expect a continuation of that trend into 2025," added David Ricks, Eli Lilly's chief executive. However, he said the ...
News Release - Eli Lilly and Company
Feb 6, 2024 · New Products(i) revenue grew by $2.19 billion to $2.49 billion in Q4 2023, led by Mounjaro and Zepbound. Growth Products(ii) revenue increased 9% to $5.27 billion in Q4 2023, led by Verzenio and Jardiance.
Eli Lilly Cuts Q4 Sales Forecast: ETFs to Buy on the Dip
23 hours ago · Eli Lilly also cut its revenue guidance for full-year 2024 to $45 billion from the previous expectation of $45.4-$46 billion. The new outlook still indicates 32% year-over-year growth in revenues.
Eli Lilly Cuts Q4 Revenue Guidance, Expects Around $5.5
1 day ago · Eli Lilly expects 2024 revenue of $45.0 billion, reflecting a 32% increase, with strong contributions from Mounjaro and Zepbound. The 2025 outlook forecasts up to $61 billion.